Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 17;319(15):1613-1614.
doi: 10.1001/jama.2018.2611.

Evaluation and Treatment of Hirsutism in Premenopausal Women

Mizuho S Mimoto  1 , Julie L Oyler  1 , Andrew M Davis  1
Affiliations

Evaluation and Treatment of Hirsutism in Premenopausal Women

Mizuho S Mimoto et al. JAMA. .

Abstract

GUIDELINE TITLE: Evaluation and Treatment of Hirsutism in Premenopausal Women

DEVELOPER: Endocrine Society, Androgen Excess and Polycystic Ovary Syndrome Society, European Society of Endocrinology

RELEASE DATE: March 2018

PRIOR VERSION: February 5, 2008

FUNDING SOURCE: Endocrine Society

TARGET POPULATION: Premenopausal women with excess hair growth

Diagnosis:

  1. Obtain a random serum total testosterone measurement to assess for androgen excess in all women with an abnormal hirsutism score (weak recommendation, low-quality evidence).

  2. Obtain an early-morning 17-hydroxyprogesterone measurement in all women with elevated testosterone and in women with hirsutism who are at high risk of congenital adrenal hyperplasia (weak recommendation; low-quality evidence).

  3. Do not measure androgen levels in women with normal menses and a normal hirsutism score (weak recommendation; low-quality evidence).

Pharmacologic treatment:

  1. Start with pharmacologic therapy and add direct hair removal methods for women with a normal hirsutism score but patient-important hirsutism despite shaving or plucking (weak recommendation; very low-quality evidence). In women who are not seeking pregnancy, oral contraceptive pills (OCPs) are recommended as initial therapy (weak recommendation; low-quality evidence).

  2. Either OCPs or antiandrogens are acceptable initial therapies in women who are not sexually active, have undergone permanent sterilization, or are using long-acting reversible contraception (weak recommendation; very low-quality evidence).

  3. Combination therapy with an antiandrogen is recommended if patient-important hirsutism persists despite 6 months of monotherapy with an OCP (weak recommendation; low-quality evidence).

PubMed Disclaimer

References

    1. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline [published online March 7, 2018] J Clin Endocrinol Metab. https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2018-00241. - DOI - PubMed
    1. Pasch L, He SY, Huddleston H, et al. Clinician vs self-ratings of hirsutism in patients with polycystic ovarian syndrome. JAMA Dermatol. 2016;152(7):783–788. - PubMed
    1. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women. J Clin Endocrinol Metab. 2008;93(4):1105–1120. - PubMed
    1. Rosner W, Auchus RJ, Azziz R, et al. Utility, limitations, and pitfalls in measuring testosterone. J Clin Endocrinol Metab. 2007;92(2):405–413. - PubMed
    1. Sam S, Ehrmann DA. Hormonal evaluation of hyperandrogenism in women. JAMA. 2015;314(23):2557–2558. - PubMed